In recent years, the use of erythropoietin (EPO) due to its neuroprotective effect on glial cells, anti-inflammatory, anti-apoptotic, and anti-oxidant effects, as well as ability to improve the blood supply to damaged tissue has been recognized as a promising therapeutic method that can improve the visual acuity of patients suffering from different types of optic neuropathies (Pakravan et al. 2016). This evidence concerns the gene EPO and Optic neuropathy.